

## **Supplementary information**

### **TITLE:**

**Circulating tumor cells detection in tumor draining vein of breast cancer patients**

### **AUTHORS:**

Masaya Hattori<sup>1</sup>, Hayao Nakanishi<sup>2, 3</sup>, Mayumi Yoshimura<sup>2</sup>, Madoka Iwase<sup>1</sup>, Akiyo Yoshimura<sup>1</sup>, Yayoi Adachi<sup>1</sup>, Naomi Gondo<sup>1</sup>, Haruru Kotani<sup>1</sup>, Masataka Sawaki<sup>1</sup>, Nao Fujita<sup>2</sup>, Yasushi Yatabe<sup>2</sup> and Hiroji Iwata<sup>1</sup>

### **AFFILIATIONS:**

<sup>1</sup> Department of Breast Oncology, Aichi Cancer Center, 1-1  
Kanokoden, Chikusa, Nagoya, 464-8681, Japan

<sup>2</sup> Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, 1-1,  
Kanokoden, Chikusa, Nagoya 464-8681, Japan

<sup>3</sup> Laboratory of Pathology and Clinical Research, Aichi Cancer Center Aichi Hospital,  
18 Kuriyada Kakemachi, Okazaki, 444-0011, Japan

### **CORRESPONDING AUTHOR:**

Masaya Hattori, MD

1-1 Kanokoden, Chikusa, Nagoya, 464-8681, Japan

Phone: +81-52-762-6111

Fax: +81-52-764-2963

Email: [mhattori@aichi-cc.jp](mailto:mhattori@aichi-cc.jp)

**Supplementary Table 1.**

CTC numbers and survival outcome in 8 patients who achieved pathological complete response

Patient No.	Age	ER and/or PR	HER2	DB volume (ml)	CTC numbers in DB	CTC numbers in PB (/10ml)	Survival outcome
1	52	Positive	Positive	2.0	0	0	No recurrence
2	57	Negative	Positive	1.0	11	0	No recurrence
3	36	Positive	Negative	0.2	11	0	No recurrence
4	44	Negative	Negative	0.2	0	3	No recurrence
5	64	Negative	Positive	0.6	6	3	No recurrence
6	58	Negative	Positive	0.2	32	8	No recurrence
7	48	Positive	Positive	0.3	52	14	No recurrence
8	67	Negative	Negative	3.0	19	23	No recurrence

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor-2; DB, draining vein blood; PB, peripheral blood, CTC circulating tumor cell.